Final outcomes of escalated melphalan 280 mg/m 2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
Parameswaran Hari, Donna E. Reece, Jasleen Randhawa, Neal Flomenberg, Dianna S. Howard, Ashrof Z. Badros, Aaron P. Rapoport, Barry R. Meisenberg, Joanne Filicko-Ohara, Gordon L. Phillips, David H. Vesole
Dive into the research topics of 'Final outcomes of escalated melphalan 280 mg/m 2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival'. Together they form a unique fingerprint.